checkAd

     121  0 Kommentare Organicell Welcomes Howard Golub, MD, PhD As Its New EVP/CSO

    FORT LAUDERDALE, FL / ACCESSWIRE / June 29, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce …

    FORT LAUDERDALE, FL / ACCESSWIRE / June 29, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce the appointment of Howard L. Golub, MD, PhD as its new Executive Vice President (EVP) and Chief Science Officer (CSO). Dr. Golub has a distinguished background as a highly innovative healthcare executive and entrepreneur with extensive experience serving in C-suite roles - in both early-stage and large companies.

    Dr. Golub's exceptional career spans over 30 years of success advancing breakthroughs in the development of clinical therapeutics. Dr. Golub is the founder and a principal at Care-Safe LLC - a clinical research consulting company that supported many biotech/drug/medical device companies to successfully develop and execute clinical research programs. He also served as Vice President of Research and Development at Walgreens Boots Alliance where he developed an innovative program utilizing Walgreen's massive customer database to power clinical trial patient recruitment. Earlier, Dr. Golub was a founder and CEO of CareStat LLC, a 150-person Clinical Research Organization (CRO) in the Boston Area, which was sold in 2008. Throughout his career, Dr. Golub has been a highly successful serial entrepreneur. He was a founder and served as CEO of 3 early-stage healthcare companies - two of which had successful exits.

    Currently Dr. Golub also serves as one of the Clinical Leads for an N.I.H. program designed to develop and accelerate accurate COVID-19 testing programs and bring them to market. In addition, from 2003 to 2013 he held an adjunct professorship at the Harvard-M.I.T. joint MS, MBA program and taught a course entitled "Clinical Development for Private Enterprise." Dr. Golub received his Ph.D. in biomedical engineering and an M.D. from that same prestigious Harvard Medical School-M.I.T. joint program.

    "Dr. Golub has a remarkable track record as a healthcare executive and nationally recognized clinical research expert. He and his companies have accelerated the development of many drug and biologic therapies for a diverse group of biotech and pharmaceutical companies," said Harry Leider, MD, MBA, Chief Executive Officer of Organicell. Dr. Leider added, "We are thrilled to have Howie join Organicell as Executive Vice President and Chief Science Officer to lead our innovative regenerative medicine research programs."

    Seite 1 von 3



    Aktuelle Themen


    Accesswire
    0 Follower
    Autor folgen
    Mehr anzeigen
    We’re a newswire service standout and fast becoming an industry disruptor. We provide regional, national and global news to thousands of clients around the world. We’re also leading the way in social engagement, targeting and analytics.
    Mehr anzeigen

    Verfasst von Accesswire
    Organicell Welcomes Howard Golub, MD, PhD As Its New EVP/CSO FORT LAUDERDALE, FL / ACCESSWIRE / June 29, 2023 / Organicell Regenerative Medicine, Inc. (OTCQB:OCEL), a clinical-stage biopharmaceutical company focused on the development of innovative biological regenerative therapeutics, is pleased to announce …

    Schreibe Deinen Kommentar

    Disclaimer